Relationship Between Metrnl Expression, IL-1β, and TNF-α in Patients With Peri-Implantitis

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAtaturk University

About this trial

Peri-implantitis is an inflammatory disease affecting the tissues around dental implants and may lead to progressive bone loss and implant failure. Current diagnosis is mainly based on clinical and radiographic findings, which may not fully reflect the underlying inflammatory activity. Therefore, there is a need for biological markers that may provide additional information about disease-related changes.

This observational study aims to compare the levels of Meteorin-like protein (Metrnl) and selected inflammatory cytokines in peri-implant crevicular fluid obtained from individuals with peri-implantitis and individuals with healthy implants. The study will evaluate Metrnl, interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10). It will also examine the relationships between Metrnl and these inflammatory markers.

The study hypothesis is that Metrnl levels differ between healthy peri-implant tissues and peri-implantitis and are associated with pro-inflammatory and anti-inflammatory cytokine levels. The findings may help clarify the possible role of Metrnl in peri-implant inflammation and its potential as a biomarker for distinguishing peri-implant health from peri-implantitis.

Eligibility criteria

Qualifiers

Individuals aged 18 years or older

Individuals without systemic disease

Individuals with at least one healthy implant or one implant affected by peri-implantitis

At least 1 year having elapsed since placement of the prosthetic restoration on the relevant implant

Disqualifiers

Pregnant or lactating individuals.

Current smokers.

Use of antibiotics or corticosteroids within the previous 6 months.

Presence of an implant-supported removable prosthesis.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

60 Participants
are grouped into 2 trial groups

Sponsors and collaborators